Screener
Kyverna Therapeutics, Inc. KYTX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Principal paid on finance lease liabilities | (86) | (341) |
| Payments for offering costs | (69) | (76) |
| Taxes paid related to net share settlement of restricted stock units | (189) | — |
| Net cash used in financing activities | (101) | (414) |
| Net decrease in cash and cash equivalents and restricted cash | (91,899) | (39,751) |
| Cash, cash equivalents and restricted cash, at beginning of period | 124,644 | 97,173 |
| Cash, cash equivalents and restricted cash, at end of period | $32,745 | $57,422 |
| Reconciliation of cash, cash equivalents and restricted cash to statement of financial position |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s financing cash flow?
- Kyverna Therapeutics, Inc. (KYTX) reported financing cash flow of -$101K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Kyverna Therapeutics, Inc.'s financing cash flow increased by 75.6% year-over-year, from -$414K to -$101K.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Kyverna Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude